Specneuzhenide
(Synonyms: 特女贞苷,Nuezhenide) 目录号 : GC37673An iridoid glycoside with diverse biological activities
Cas No.:449733-84-0
Sample solution is provided at 25 µL, 10mM.
Specneuzhenide is an iridoid glycoside originally isolated from L. lucidum with diverse biological activities.1,2,3,4 It reduces neurotoxicity induced by 6-OHDA in SH-SY5Y cells by 49.2% when used at a concentration of 10 μM.1 Specneuzhenide (25, 50, and 100 μM) reduces high glucose-induced levels of cleaved caspase-3 protein and apoptosis in mouse glomerular mesangial cells.2 It increases cell viability and alkaline phosphatase activity in osteoblastic UMR-106 cells.3 Specneuzhenide inhibits hypoxia-induced VEGFA secretion, VEGFA and prolyl hydroxylase 2 (PHD-2) mRNA expression, and protein levels of VEGFA, HIF-1α, and PHD-2 in human acute retinal pigment epithelial-19 (ARPE-19) cells.4 In vivo, specneuzhenide (5 and 10 mg/kg) prevents retinal neovascularization in a rat model of oxygen-induced retinopathy.
1.Sung, S.H., Kim, E.S., Lee, K.Y., et al.A new neuroprotective compound of Ligustrum japonicum leavesPlanta Med.72(1)62-64(2006) 2.Zhang, A.-n., Li, P., Hong, X.-h., et al.Preventive effect of specnuezhenide on high glucose-induced apoptosis in glomerular mesangial cellsZhongguo Shiyan Fangjixue Zazhi21(8)116-119(2015) 3.Huang, Y., Wu, Y., Wu, J., et al.Chemical constituents from Ligustrum lucidum differentially promote bone formation and prevent oxidative damage in osteoblastic UMR-106 cellsLat. Am. J. Pharm.33(2)258-265(2014) 4.Wu, J., Ke, X., Fu, W., et al.Inhibition of hypoxia-induced retinal angiogenesis by specnuezhenide, an effective constituent of Ligustrum lucidum Ait., through suppression of the HIF-1α/VEGF signaling pathwayMolecules21(12)E1756(2016)
Cas No. | 449733-84-0 | SDF | |
别名 | 特女贞苷,Nuezhenide | ||
Canonical SMILES | C/C=C1[C@@H](C(C(OC)=O)=CO[C@H]/1O[C@]2([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)CO)CC(OC[C@H]3O[C@H]([C@H](O)[C@@H](O)[C@@H]3O)OCCC4=CC=C(O)C=C4)=O | ||
分子式 | C31H42O17 | 分子量 | 686.65 |
溶解度 | DMSO: ≥ 100 mg/mL (145.63 mM) | 储存条件 | 4°C, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.4563 mL | 7.2817 mL | 14.5635 mL |
5 mM | 0.2913 mL | 1.4563 mL | 2.9127 mL |
10 mM | 0.1456 mL | 0.7282 mL | 1.4563 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet